SavedAdd your journal

Journals / Çocuk ve Gençlik Ruh Sağlığı Dergisi / 2020 / Cilt: 27 - Sayı: 3

Developing Therapeutic Alternatives for Treatment-resistant Bipolar Depression: The Role of Riluzole

Tedavi Dirençli Bipolar Depresyonda Gelişen Tedavi Seçenekleri: Riluzol

Sidar ÇÖPÜR
Mazlum ÇÖPÜR
Pages
199–200
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

ÇÖPÜR, S., ÇÖPÜR, M. (2022). Developing Therapeutic Alternatives for Treatment-resistant Bipolar Depression: The Role of Riluzole. Çocuk ve Gençlik Ruh Sağlığı Dergisi, Cilt: 27 - Sayı: 3, 199–200. https://ajindex.com/articles/484399

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Maria Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zahari Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68:241-251
  2. McCormick U, Murray B, McNew B. Diagnosis and treatment of patients with bipolar disorder: A review for advanced practice nurses. J Am Assoc Nurse Pract. 2015;27:530-542
  3. Machado-Vieira R, Ibrahim L, Henter ID, Zarate Jr CA. Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav. 2012;100:678-687
  4. Thompson SM, Kallarackal AJ, Kvarta MD, Van Dyke AM, LeGates TA, Cai X. An excitatory synapse hypothesis of depression. Trends Neurosci. 2015;38:279-294
  5. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB. APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry. 2015;172:950-966
  6. Bobo WV, Vande Voort JL, Croarkin PE, Leung JG, Tye SJ, Frye MA. Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depress Anxiety. 2016;33:698-710
  7. Park LT, Lener MS, Hopkins M, Iadorola N, Machado-Vieira R, Ballard E, Nugent A, Zarate Jr CA. A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression. J Clin Psychopharmacol. 2017;37:355-358
  8. Zarate CA, Jr., Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney S, Manji HK. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57:430-432
  9. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh DA, Charney S, Manji HK. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004;161:171-174
  10. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji HK, Zarate Jr CA. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012;37:1526-1533
  11. Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande V